Repaglinide-d5 |
| Katalog-Nr.GC48039 |
Repaglinid-d5 (AG-EE 623ZW D5) ist ein mit Deuterium markiertes Repaglinid.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1217709-85-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Repaglinide-d5 is intended for use as an internal standard for the quantification of repaglinide by GC- or LC-MS. Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (Kir6) channels in pancreatic β-cells (Kd = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with Kir6.2).1 In vivo, repaglinide lowers blood glucose in fasted rats and dogs (ED50s = 10 and 28.3 μg/kg, respectively).2 Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.
1.Hansen, A.M.K., Hansen, J.B., Carr, R.D., et al.Kir6.2-dependent high-affinity repaglinide binding to β-cell KATP channelsBr. J. Pharmacol.144(4)551-557(2005) 2.Mark, M., and Grell, W.Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogsBr. J. Pharmacol.121(8)1597-1604(1997)
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *